Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Methylprednisolone/pembrolizumab

Various toxicities and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chan W-N, et al. Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis. Frontiers in Oncology 12: 23 Sep 2022. Available from: URL: http://doi.org/10.3389/fonc.2022.985177 Chan W-N, et al. Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis. Frontiers in Oncology 12: 23 Sep 2022. Available from: URL: http://​doi.​org/​10.​3389/​fonc.​2022.​985177
Metadaten
Titel
Methylprednisolone/pembrolizumab
Various toxicities and lack of efficacy: case report
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30981-0

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Vosilasarm

Case report

Multiple drugs